111 related articles for article (PubMed ID: 35866833)
1. Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer.
Iede K; Yamada T; Ueda M; Tsuda Y; Nakashima S; Ohta K; Tanida T; Matsuyama J; Ikenaga M; Tominaga S
Medicine (Baltimore); 2022 Jul; 101(29):e29532. PubMed ID: 35866833
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Zhang H; Kellett C; Lambert P; Kim CA
Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Iede K; Yamada T; Kato R; Ueda M; Tsuda Y; Nakashima S; Ohta K; Matsuyama J; Ikenaga M; Tominaga S
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1215. PubMed ID: 32672000
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
5. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Emori T; Itonaga M; Ashida R; Tamura T; Kawaji Y; Hatamaru K; Yamashita Y; Shimokawa T; Koike M; Sonomura T; Kawai M; Kitano M
Pancreatology; 2022 Mar; 22(2):277-285. PubMed ID: 35033425
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Pelzer U; Wislocka L; Jühling A; Striefler J; Klein F; Roemmler-Zehrer J; Sinn M; Denecke T; Bahra M; Riess H
Eur J Cancer; 2018 Sep; 100():85-93. PubMed ID: 30014884
[TBL] [Abstract][Full Text] [Related]
10. Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer.
Iede K; Yamada T; Koh M; Ueda M; Tsuda Y; Nakashima S; Ohta K; Tanida T; Matsuyama J; Ikenaga M; Tominaga S
Pancreas; 2022 Mar; 51(3):278-281. PubMed ID: 35584386
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
Blomstrand H; Green H; Fredrikson M; Gränsmark E; Björnsson B; Elander NO
BMC Cancer; 2020 Oct; 20(1):950. PubMed ID: 33008332
[TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
13.
Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK
Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
McAndrew EN; Zhang H; Lambert P; Rittberg R; Dawe DE; Kim CA
Am J Clin Oncol; 2022 Feb; 45(2):55-60. PubMed ID: 35073280
[TBL] [Abstract][Full Text] [Related]
15. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
16. Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Relias V; Maloney A; Smith MH; Saif MW
Cancer Chemother Pharmacol; 2017 Aug; 80(2):371-375. PubMed ID: 28664225
[TBL] [Abstract][Full Text] [Related]
17. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
19. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Prager GW; Oehler L; Gerger A; Mlineritsch B; Andel J; Petzer A; Wilthoner K; Sliwa T; Pichler P; Winder T; Heibl S; Gruenberger B; Laengle F; Hubmann E; Korger M; Pecherstorfer M; Djanani A; Neumann HJ; Philipp-Abbrederis K; Wöll E; Trondl R; Arnold-Schrauf C; Eisterer W
Eur J Cancer; 2021 Jan; 143():101-112. PubMed ID: 33296830
[TBL] [Abstract][Full Text] [Related]
20. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Karasic TB; O'Hara MH; Loaiza-Bonilla A; Reiss KA; Teitelbaum UR; Borazanci E; De Jesus-Acosta A; Redlinger C; Burrell JA; Laheru DA; Von Hoff DD; Amaravadi RK; Drebin JA; O'Dwyer PJ
JAMA Oncol; 2019 Jul; 5(7):993-998. PubMed ID: 31120501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]